NSSG Chemotherapy Protocol
Myeloid group This is a controlled document and therefore must not be changed ML.54 FLAG- IDA Authorised by Myeloid Lead Prof Adam Mead Oct 2019 Version 1.1 Page 1 of 4 FLAG -IDA INDICATION Induction chemotherapy for patients with acute myeloid leukaemia (AML) or in relapse/ refractory disease (AML or ALL).
Download NSSG Chemotherapy Protocol
Information
Domain:
Source:
Link to this page:
Documents from same domain
CYCLOPHOSPHAMIDE / BORTEZOMIB/ …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed of MM.11 CyBorDex- Amyloidosis Authorised by …
Cyclophosphamide priming prior to PBSC harvest
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology Oxford BMT Programme B.2.20b Page 1 of 3 May 2017 V.5.4 Cyclo prime for Myeloma PSBC Harvest Authorised by: Dr Karthik Ramasamy
ATTENUATED CYCLOPHOSPHAMIDE, THALIDOMIDE & …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed MM.9 CTD - attenuated Authorised by Myeloma lead Dr. Karthik Ramasamy July 2017
Guidelines for the Management of Hypomagnesaemia …
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology H.95 Page 2 of 5 November 2015 V.1.0. Guidelines for the management of hypomagnesaemia in Adult Clinical Haematology
Oxford Myeloma Group
nssg.oxford-haematology.org.ukMM.50 VTDPACE/DTPACE Authorised by Myeloma lead Dr. Karthik Ramasamy June 2022 V. 2.0 of 10 Days Drug Dose Route Comments 1 to 4 Dexamethasone 40 mg daily Oral Continuous daily/ If PBSC harvest planned only for days 1 to 4 Thalidomide (See note below) Start 50 mg and increase up to 100 mg as tolerated Oral Nocte 1 to 4
MATRix (High dose METHOTREXATE, high dose CYTARABINE ...
nssg.oxford-haematology.org.uk- Reduce thiotepa dose to 75% - Reduce methotrexate to 2g/m2 Haematological toxicity In case if inadequate bone marrow recovery (i.e. neutrophils < 1.5x109/L and platelets < 90x109/L on the intended day of re-treatment, delay cycle until counts satisfactory. Doses of the chemotherapy
ISATUXIMAB WITH POMALIDOMIDE AND …
nssg.oxford-haematology.org.ukvolume Initial rate Absence of infusion reaction Rate increment Maximum rate First infusion 250 mL 25 mL/ hour For 60 minutes 25 mL/hour every 30 minutes 150 mL/ hour Second infusion 250 mL 50 mL/ hour For 30 minutes 50 mL/ hour for 30 minutes then increase by 100 mL/ hr every 30 minutes 200 mL/ hour Subsequent infusions
ATRA + ARSENIC TRIOXIDE
nssg.oxford-haematology.org.ukArsenic Trioxide infusion duration may be extended up to 4 hours if vasomotor reactions, e.g. flushing, tachycardia and dizziness, are observed. If patients suffer severe symptoms or hypotension then the infusion should be stopped until recovery and then recommenced at a
High dose METHOTREXATE (high grade NHL CNS …
nssg.oxford-haematology.org.ukadults receiving high-dose methotrexate chemotherapy (doses >1g/m2) - Who develop significant deterioration in renal function (>1.5x ULN and rising, or the presence of oliguria) OR - Have toxic plasma methotrexate level AND - Have been treated with all standard rescue and supportive measures AND
ESHAP and R-ESHAP
nssg.oxford-haematology.org.uk2. Record stage of disease - contrast enhanced CT scan (neck, chest, abdomen and pelvis), ... In order to eliminate the risk of transmitting infective ... After 1-2 cycles with CT or PET-CT. Lymphoma group This is a controlled document and therefore must …
Related documents
Acute Myeloid Leukemia: A Review
www.rimed.orgAcute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage (red blood cells, platelets, and white blood cells other than B and T cells). Like other malignancies, it is due to genetic variations that lead to neoplastic changes and clonal pro -
Leukemia: AML, CML, ALL and CLL - - RN.org®
www.rn.orgleukemia (ALL), acute myelogenous leukemia (AML) or acute nonlymphoblastic leukemia (ANLL), chronic myelogenous leukemia (CML), and chronic lymphocytic leukemia (CLL) with a number of subtypes. Leukemias are often referred to by a number of different names, depending on the involved cell, and this can be confusing at times. Acute and chronic ...
Myeloid Malignancies
www.cdc.govFeb 01, 2014 · Acute myeloid leukemia. AML results from the clonal expansion of myeloid blasts in the peripheral blood, bone marrow or other tissue. It is caused when either the myeloid stem cells produce abnormal myeloblasts which do not become healthy white blood cells or too many myeloid stem cells become abnormal red blood cells or platelets.
Acute Promyelocytic Leukemia Facts
www.lls.orgMay 07, 2015 · Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia. APL is classified as the M3 subtype of AML according to the French-American-British (FAB) system and as APL with translocation between chromosomes 15 and 17 [ t(15;17) ] in the World Health Organization (WHO) classification system. It accounts for about 10 to
NCCN Guidelines for Patients Acute Lymphoblastic Leukemia
www.nccn.orgAcute Lymphoblastic Leukemia, 2021 1 ALL basics Blood Acute lymphoblastic leukemia (ALL) is a fast-growing cancer that starts in lymphocytes, a type of white blood cell. In ALL, bone marrow makes too many immature lymphocytes called lymphoblasts. Lymphoblasts can crowd out other blood cells causing blood to not work as it should. Treatment depends
NCCN.org/patients/survey Chronic Lymphocytic Leukemia
www.nccn.orgAcute myeloid leukemia (AML) affects myeloid cells that make many abnormal myeloblasts. Chronic leukemia Chronic leukemia often worsens slowly. People with chronic leukemia may not have symptoms or need treatment right away. Chronic leukemia affects mature blood cells.
Acute lymphoblastic leukemia: a comprehensive review and ...
www.who.intAcute lymphoblastic leukemia: a comprehensive review and 2017 update T Terwilliger1 and M Abdul-Hay1,2 Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per year in the United States alone. The hallmark of ALL is chromosomal abnormalities and genetic alterations involved in